Login to Your Account



Financings Roundup

Cebix Closes $30.9M Series B, Reports Phase II Ersatta Data

By Catherine Shaffer
Staff Writer

Thursday, October 18, 2012

Cebix Inc., of La Jolla, Calif., closed a $30.9 million Series B investment to support development of its investigational drug for peripheral neuropathy, Ersatta. It also reported new results from a Phase I/II trial showing the drug had efficacy in patients with Type I diabetes dosed once weekly for 12 weeks.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription